Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma

IF 7.6 2区 医学 Q1 HEMATOLOGY HemaSphere Pub Date : 2024-06-03 DOI:10.1002/hem3.84
Berit Müller-Meinhard, Nicole Seifert, Johanna Grund, Sarah Reinke, Fatih Yalcin, Helen Kaul, Sven Borchmann, Bastian von Tresckow, Peter Borchmann, Annette Plütschow, Julia Richter, Andreas Engert, Michael Altenbuchinger, Paul J. Bröckelmann, Wolfram Klapper
{"title":"Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma","authors":"Berit Müller-Meinhard,&nbsp;Nicole Seifert,&nbsp;Johanna Grund,&nbsp;Sarah Reinke,&nbsp;Fatih Yalcin,&nbsp;Helen Kaul,&nbsp;Sven Borchmann,&nbsp;Bastian von Tresckow,&nbsp;Peter Borchmann,&nbsp;Annette Plütschow,&nbsp;Julia Richter,&nbsp;Andreas Engert,&nbsp;Michael Altenbuchinger,&nbsp;Paul J. Bröckelmann,&nbsp;Wolfram Klapper","doi":"10.1002/hem3.84","DOIUrl":null,"url":null,"abstract":"<p>Hodgkin–Reed–Sternberg cells (HRSCs) in classic Hodgkin Lymphoma (HL) frequently lack expression of human leukocyte antigen class I (HLA-I), considered to hamper activation of cytotoxic T cells in the tumor microenvironment (TME). Here, we demonstrate HLA-I expression on HRSCs to be a strong determinant of TME composition whereas expression of HLA-II was associated with only minor differential gene expression in the TME. In HLA-I-positive HL the HRSC content and expression of CCL17/TARC in HRSCs are low, independent of the presence of Epstein–Barr virus in HRSCs. Additionally, HLA-I-positive HL shows a high content of CD8+ cytotoxic T cells. However, an increased expression of the inhibitory immune checkpoint LAG3 on CD8+ T cells in close proximity to HRSCs is observed. Suggesting interference with cytotoxic activity, we observed an absence of clonally expanded T cells in the TME. While HLA-I-positive HL is not associated with an unfavorable clinical course in our cohorts, they share features with the recently described H2 subtype of HL. Given the major differences in TME composition, immune checkpoint inhibitors may differ in their mechanism of action in HLA-I-positive compared to HLA-I-negative HL.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 6","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.84","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.84","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hodgkin–Reed–Sternberg cells (HRSCs) in classic Hodgkin Lymphoma (HL) frequently lack expression of human leukocyte antigen class I (HLA-I), considered to hamper activation of cytotoxic T cells in the tumor microenvironment (TME). Here, we demonstrate HLA-I expression on HRSCs to be a strong determinant of TME composition whereas expression of HLA-II was associated with only minor differential gene expression in the TME. In HLA-I-positive HL the HRSC content and expression of CCL17/TARC in HRSCs are low, independent of the presence of Epstein–Barr virus in HRSCs. Additionally, HLA-I-positive HL shows a high content of CD8+ cytotoxic T cells. However, an increased expression of the inhibitory immune checkpoint LAG3 on CD8+ T cells in close proximity to HRSCs is observed. Suggesting interference with cytotoxic activity, we observed an absence of clonally expanded T cells in the TME. While HLA-I-positive HL is not associated with an unfavorable clinical course in our cohorts, they share features with the recently described H2 subtype of HL. Given the major differences in TME composition, immune checkpoint inhibitors may differ in their mechanism of action in HLA-I-positive compared to HLA-I-negative HL.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
霍奇金-里德-斯登堡细胞上人类白细胞抗原(HLA)Ⅰ类的表达是典型霍奇金淋巴瘤微环境组成的主要决定因素,与 EBV 无关
典型霍奇金淋巴瘤(HL)中的霍奇金-里德-斯登堡细胞(HRSCs)经常缺乏人类白细胞抗原I类(HLA-I)的表达,这被认为会阻碍肿瘤微环境(TME)中细胞毒性T细胞的活化。在这里,我们证明了HRSCs上HLA-I的表达是TME组成的一个重要决定因素,而HLA-II的表达只与TME中微小的差异基因表达有关。在HLA-I阳性的HL中,HRSCs的含量和CCL17/TARC的表达量都很低,这与HRSCs中是否存在Epstein-Barr病毒无关。此外,HLA-I 阳性 HL 显示出 CD8+ 细胞毒性 T 细胞的高含量。不过,在靠近 HRSCs 的 CD8+ T 细胞上,抑制性免疫检查点 LAG3 的表达量有所增加。我们观察到TME中没有克隆扩增的T细胞,这表明细胞毒性活性受到干扰。虽然在我们的队列中,HLA-I 阳性 HL 与不利的临床病程无关,但它们与最近描述的 H2 亚型 HL 有着共同的特征。鉴于TME组成的重大差异,免疫检查点抑制剂在HLA-I阳性与HLA-I阴性HL中的作用机制可能有所不同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
HemaSphere
HemaSphere Medicine-Hematology
CiteScore
6.10
自引率
4.50%
发文量
2776
审稿时长
7 weeks
期刊介绍: HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.
期刊最新文献
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA–CAR-T cell therapy: A retrospective study based on LEGEND-2 Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population-based screening study A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells IL-11—An aging-related cytokine with opportunities for regulating hematopoiesis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1